Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.39B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.18M
Average 0.08M
Financial health
Nanobiotix S.A. financial health
Start with the overall verdict and the rule-based risk checks for NBTX, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
The balance sheet looks mixed, so liquidity and debt trends deserve a closer read.
Cash & Investments
$52.75M
Debt Cushion
-$42.57M
Current Ratio
1.1x
Interest Coverage
Not available
Risk checks
5 of 9 checks flagged
Positive equity
Negative
Passes when: Shareholders’ equity is above zero.
Interest coverage
-1.0×
Passes when: Operating income is at least 1.5 times interest expense.
Manageable net debt
Negative EBITDA
Passes when: Net debt is below 3 times EBITDA.
Debt repayment from cash flow
Negative FCF
Passes when: Free cash flow could repay all debt within 5 years.
Share dilution
+14.4% per year
Passes when: Diluted share count grows no more than 2% per year.
Short-term liquidity
1.1×
Passes when: Current assets are at least 1 times current liabilities.
Near-term debt coverage
17.0×
Passes when: Cash and short-term investments cover debt due within 12 months.
Debt growth versus revenue growth
21.5% vs. 83.8%
Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.
Altman Z-score trend
-4.23 → 3.22
Passes when: The Z-score is stable or rising, or stays above 2.99.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Weak2 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Safe zone4.25
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | 3 | 4 | 2 | 1 | 4 | 2 | 2 | 5 | — | — |
| Altman Z | 8.90 | 9.81 | 3.27 | 0.09 | 2.83 | 0.32 | -2.72 | 0.85 | -4.23 | 3.22 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$52.75M
Q4 2025
Quick Ratio
1.1x
Q4 2025
Current Ratio
1.1x
Q4 2025
Cash Ratio
0.9x
Q4 2025
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q4 2025)
€5.24M
Current assets − current liabilities
Days sales outstanding
95 d
How long customers take to pay
Days inventory outstanding
—
How long stock sits before sale
Days payables outstanding
—
How long the company takes to pay suppliers
Cash conversion cycle
—
Receivable + inventory days − payable days
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$95.32M
Q4 2025
Debt/Equity
-1.1x
Q4 2025
Debt/Assets
1.4x
Q4 2025
Interest Coverage
—
Q4 2025
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
€42.57M
Total debt − cash − short-term investments
Net debt / EBITDA
Negative EBITDA
Above 3× is elevated
Free cash flow / debt
-35.6%
Share of debt one year of FCF could repay
Years to repay debt
Negative FCF
Total debt ÷ free cash flow
Operating cash flow / current liabilities
-0.6×
Above 1× funds a year of obligations
Interest coverage
-1.0×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 17.0×.
Balance sheet as of Q4 2025; cash flows FY 2025.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$0.00
Q4 2025
Assets
$67.76M
Q4 2025
Liabilities
$152.24M
Q4 2025
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q4 2025).
€152.24M in liabilities against €67.76M in assets
- Payables4.3%
- Short-term debt2.0%
- Long-term debt58.5%
- Deferred revenue23.8%
- Other liabilities11.3%
Shareholders' equity is negative (-€84.48M), so liabilities exceed total assets. Buybacks funded with debt are a common cause; check whether cash flow supports the debt.
Goodwill + intangibles
€10K
0.0% of total assets
Share of equity
Negative equity
Above 50% leaves little tangible backing
Tangible equity
-€84.49M
Equity left after writing off goodwill and intangibles
Deferred revenue
€36.22M
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does Nanobiotix S.A. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
ImmunityBio, Inc. IBRX:NASDAQ | $6.40B | -1.76 | 1.75 | Net cash | — | 5.08 | 5.10 | 1.43 |
Tyra Biosciences, Inc. TYRA:NASDAQ | $1.38B | 0.02 | 0.02 | 0.60 | — | 14.67 | 14.67 | 4.28 |
Syndax Pharmaceuticals, Inc. SNDX:NASDAQ | $850.77M | 5.36 | 0.65 | Net cash | — | 4.12 | 4.40 | 1.12 |
Kura Oncology, Inc. KURA:NASDAQ | $713.90M | 0.12 | 0.03 | 0.47 | — | 6.05 | 6.06 | 1.27 |
Nuvectis Pharma, Inc. NVCT:NASDAQ | $696.03M | 0.00 | 0.00 | 1.20 | — | 2.38 | 2.38 | 2.38 |
ArriVent BioPharma, Inc. AVBP:NASDAQ | $672.92M | 0.00 | 0.00 | 0.27 | — | 12.83 | 12.83 | 1.76 |
Immix Biopharma, Inc. IMMX:NASDAQ | $649.96M | 0.01 | 0.01 | 3.20 | — | 10.01 | 10.01 | 9.29 |
Candel Therapeutics, Inc. CADL:NASDAQ | $474.42M | 0.04 | 0.02 | 3.35 | — | 13.31 | 13.31 | 13.31 |
Puma Biotechnology, Inc. PBYI:NASDAQ | $401.70M | 0.22 | 0.13 | Net cash | 5.63 | 1.93 | 2.00 | 0.36 |
Black Diamond Therapeutics, Inc. BDTX:NASDAQ | $84.48M | 0.17 | 0.13 | Net cash | — | 8.42 | 8.42 | 1.33 |
Questions
Financial health questions
Common questions about NBTX's balance sheet, answered from the reported figures.
Is NBTX's balance sheet healthy?
Nanobiotix S.A. (NBTX) has a current ratio of 1.09, a quick read on short-term liquidity.
How leveraged is NBTX?
Debt to equity is -1.13, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.